Metastasis in renal cell carcinoma: Biology and implications for therapy

Asian Journal of Urology, 2016, 3 (4): 286-292 doi:

Review

Metastasis in renal cell carcinoma: Biology and implications for therapy

Jun Gong^a, Manuel Caitano Maia^b, Nazli Dizman^c, Ameish Govindarajan^a, Sumanta K. Pal^a

a Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA;
b Division of Medical Oncology, Instituto Hemomed de Oncologia e Hematologia. Av. Arnolfo de Azevedo, 121-Cerqueira César-CEP 01248-040, Sao Paulo, Brazil;
c Department of Internal Medicine, Istanbul Medeniyet University Goztepe Research and Training Hospital, Istanbul, Turkey

Abstract
Related Citation (12)

[1]	National comprehensive cancer network clinical practice guidelines:renal cell carcinoma. Available at:http://www. nccn.org;[accessed 15.08.16].
[2]	Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96.
[3]	Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96.
[4]	Pal SK, Kortylewski M, Yu H, Figlin RA. Breaking through a plateau in renal cell carcinoma therapeutics:development and incorporation of biomarkers. Mol Cancer Ther 2010;9:3115-25.
[5]	Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma:results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8.
[6]	Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma:a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
[7]	Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
[8]	Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl J Med 2007;356:2271-81.
[9]	Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS):a randomised phase 3 trial. Lancet 2011;378:1931-9.
[10]	Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma:final results of CALGB 90206. J Clin Oncol 2010;28:2137-43.
[11]	Pal SK, Choueiri TK, Karam JA, Heng DY. Metastatic renal cell carcinoma:contending with a sea change in therapy. Urol Oncol 2015;33:507-8.
[12]	Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. New Engl J Med 2015;373(19):1803-13.
[13]	Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma:a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015;16:1473-82.
[14]	Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR):final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17(7):917-27.
[15]	Pal SK, Figlin RA. Targeted therapies for renal cell carcinoma:understanding their impact on survival. Target Oncol 2010;5:131-8.
[16]	Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22:4991-5004.
[17]	Zhou L, Liu XD, Sun M, Zhang X, German P, Bai S, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 2016;35(21):2687-97.
[18]	Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. New Engl J Med 2016;374:135-45.
[19]	Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 2014;26:319-30.
[20]	Pal SK, Choueiri TK, Wang K, Khaira D, Karam JA, Van Allen E, et al. Characterization of clinical cases of collecting duct carcinoma of the kidney assessed by comprehensive genomic profiling. Eur Urol 2016;70(3):516-21.
[21]	Shuch B, Bratslavsky G, Linehan WM, Srinivasan R. Sarcomatoid renal cell carcinoma:a comprehensive review of the biology and current treatment strategies. Oncologist 2012;17:46-54.
[22]	Malouf GG, Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, et al. Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations. Eur Urol 2016;70:348-57.
[23]	Pal SK, He M, Tong T, Wu H, Liu X, Lau C, et al. RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. Mol Cancer Res 2015;13:130-7.
[24]	Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
[25]	Callea M, Albiges L, Gupta M, Cheng SC, Genega EM, Fay AP, et al. Differential expression of PD-L1 between primary and metastatic sites in clear cell renal cell carcinoma. Cancer Immunol Res 2015;3(10):1158-64.
[26]	Grange C, Tapparo M, Collino F, Vitillo L, Damasco C, Deregibus MC, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res 2011;71:5346-56.
[27]	Lopez-Lago MA, Posner S, Thodima VJ, Molina AM, Motzer RJ, Chaganti RS. Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression. Oncogene 2013;32:1752-60.
[28]	Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated antiangiogenic therapy. Int Immunopharmacol 2011;11:856-61.
[29]	Razorenova OV, Finger EC, Colavitti R, Chernikova SB, Boiko AD, Chan CK, et al. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{δ}-driven migration. Proc Natl Acad Sci U S A 2011;108:1931-6.
[30]	Aubert S, Fauquette V, Hemon B, Lepoivre R, Briez N, Bernard D, et al. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res 2009;69:5707-15.
[31]	Struckmann K, Mertz K, Steu S, Storz M, Staller P, Krek W, et al. pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. J Pathol 2008;214:464-71.
[32]	Pal SK, Haas NB. Adjuvant therapy for renal cell carcinoma:past, present, and future. Oncologist 2014;19:851-9.
[33]	Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805):a doubleblind, placebo-controlled, randomised, phase 3 trial. Lancet 2016;387:2008-16.
[34]	Pfizer announces positive top-line results from phase 3 S-TRAC trial of SUTENT®(sunitinib) as adjuvant therapy in patients at high risk of recurrent renal cell carcinoma. Available at:http://www.pfizer.com;[accessed 15.08.16].
[35]	Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P. Risk score and metastasectomy independently impact prognosis in patients with recurrent renal cell carcinoma. J Urol 2008;180:873-8.
[36]	Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, et al. Distribution of metastatic sites in renal cell carcinoma:a population-based analysis. Ann Oncol 2012;23:973-80.
[37]	McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 2014;65:577-84.
[38]	Vickers MM, Al-Harbi H, Choueiri TK, Kollmannsberger C, North S, MacKenzie M, et al. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy:results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer 2013;11:311-5.
[39]	Hegde U, Patel V, Kaloudis E. Durable spontaneous regression of lung metastases from renal cell carcinoma after incomplete use of multiple kinase inhibitor sorafenib. Int J Urol 2013;20:644-5.
[40]	Nicholls MF, Siddons AH. Spontaneous disappearance of lung metastases in a case of kidney carcinoma (hypernephroma). Brit J Surg 1960;47:531-3.
[41]	Nishida H, Shirai T, Hayashi K, Takeuchi A, Tanzawa Y, Mizokami A, et al. Cryotreatment against metastatic renal cell bone tumour reduced multiple lung metastases. Anticancer Res 2011;31:2927-30.
[42]	Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, et al. Cabozantinib in patients with advanced prostate cancer:results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31:412-9.
[43]	Escudier BJ, Powles T, Motzer RJ, Olencki T, Aren OR, Oudard S, et al. Efficacy of cabozantinib (C) vs. everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study. J Clin Oncol 2016;34:4558. ASCO Meeting Abstracts.
[44]	Dudek AZ, Raza A, Chi M, Singhal M, Oberoi R, Mittapalli RK, et al. Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clin Genitourin Cancer 2013;11:155-60.